Integration problems and turnaround strategies in a cross-border merger A clinical examination of the Pharmacia-Upjohn merger

International Review of Financial Analysis

Volumn 9, Issue 2, 2000, Pages 219-234

  Belcher, Terry ^a,b   Nail, Lance ^b  

^a AUBURN UNIVERSITY AT MONTGOMERY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Acquisition; Corporate integration; Culture clash; F3; G3; International merger; Merger

Indexed keywords

EID: 0043230070     PISSN: 10575219     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1057-5219(00)00034-X     Document Type: Article

References (8)

1. Baily M. Research and development costs and returns. the U.S. pharmaceutical industry Journal of Political Economy. 80:1972;70-85.
2. Barber B.M., Lyon J. Detecting long-run abnormal stock returns. The empirical power and specification of test statistics Journal of Financial Economics. 43:1997;341-372.
3. Bradley M., Desai A., Kim E.H. Synergistic gains from corporate acquisitions and their division between the stockholders of target and acquiring firms. Journal of Financial Economics. 21:1988;3-40.
4. Comanor W.S. The political economy of the pharmaceutical industry. Journal of Economic Literature. 24:1986;1178-1217.
5. Harris R., Ravenscraft D. The role of acquisitions in foreign direct investment. evidence from the U.S. stock market Journal of Finance. 46:1991;825-844.
6. Reekie D. Price and quality competition in the U.S. drug industry. Journal of Industrial Economics. 26:1978;223-237.
7. Maquieira C., Megginson W., Nail L. Wealth creation versus redistributions in pure stock-for-stock mergers. Journal of Financial Economics. 48:1998;3-33.
8. Zweifel P., Breyer F. Health economics. 1997;Oxford University Press, New York.